Drug Search Results
More Filters [+]

Rebimastat

Alternative Names: rebimastat, bms-275291, bms275291, bms 275291
Latest Update: 2020-03-25
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rebimastat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Prostate Cancer|Adenocarcinoma|Breast Cancer|Sarcoma, Kaposi|Bone Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2013-00041

P2

Completed

Bone Cancer|Prostate Cancer|Adenocarcinoma

2006-07-01

NCI-2012-02799

P2

Completed

Prostate Cancer|Adenocarcinoma

2005-01-01

BR18

P3

Completed

Non-Small-Cell Lung Cancer

2003-12-10

NCI-2012-02410

P2

Completed

Sarcoma, Kaposi

2003-08-01

Recent News Events

Date

Type

Title